Norepinephrine Dosing for Septic Shock
Start norepinephrine at 2-3 mL/min (8-12 mcg/min) of a standard dilution (4 mcg/mL), then titrate to achieve a mean arterial pressure (MAP) of 65 mmHg, with typical maintenance doses ranging from 2-4 mcg/min (0.5-1 mL/min), though doses may need to be substantially higher in refractory cases. 1
Initial Dosing Strategy
The FDA-approved dosing protocol provides clear guidance 1:
- Standard dilution: Add 4 mg norepinephrine to 1000 mL of 5% dextrose solution (creates 4 mcg/mL concentration)
- Starting dose: 8-12 mcg/min (2-3 mL/min of standard dilution)
- Maintenance range: 2-4 mcg/min (0.5-1 mL/min)
- Target: MAP of 65 mmHg per Surviving Sepsis Campaign guidelines 2
Weight-Based vs. Non-Weight-Based Dosing
Recent evidence suggests non-weight-based dosing may be more practical and equally effective. A 2023 study demonstrated that weight-based dosing actually resulted in lower absolute norepinephrine doses at goal MAP (median 0.05 mcg/kg/min vs 0.07 mcg/kg/min, p<0.005), with no difference in time to achieve target MAP 3. This is particularly relevant in obese patients, who require lower weight-based doses but similar total doses compared to non-obese patients 4.
Practical approach: Start with absolute dosing (8-12 mcg/min) rather than calculating weight-based doses, as this achieves hemodynamic goals efficiently across all body habitus types.
Dose Escalation and High-Dose Considerations
The dose range can vary dramatically based on severity:
- Moderate shock: Most patients respond to 2-20 mcg/min
- Severe refractory shock: Doses up to 68 mg/day (approximately 47 mcg/min) have been safely used 1
- Very high doses: Doses exceeding 4 mcg/kg/min (roughly 280 mcg/min in a 70kg patient) can be safe and effective in catecholamine-resistant shock, with survival rates of 33% in otherwise fatal cases 5
A 2026 retrospective study identified four clinically relevant dose ranges with stepwise mortality increases 6:
- 0.05-0.6 mcg/kg/min: ICU mortality 20.7%
- 0.61-1.2 mcg/kg/min: ICU mortality increases (OR 1.88)
- 1.2-3.0 mcg/kg/min: ICU mortality further increases (OR 2.55)
- >3.0 mcg/kg/min: 100% mortality
Critical caveat: Before escalating to very high doses, always reassess for occult hypovolemia, as inadequate fluid resuscitation is the most common reason for apparent norepinephrine resistance 1.
Timing of Initiation
Early norepinephrine initiation is increasingly supported, particularly in profound hypotension:
- Meta-analysis of RCTs and propensity-matched studies shows early initiation reduces mortality (OR 0.49-0.71) 7
- Greatest benefit when initiated within 1 hour and when lactate ≤3 mmol/L 7
- Early use reduces total fluid volume at 6 hours (by ~500 mL) and achieves MAP targets 1.3 hours faster 7
Prioritize early norepinephrine when 8:
- Diastolic blood pressure ≤40 mmHg
- Diastolic shock index (HR/DBP) ≥3
- Acute respiratory distress syndrome present (to minimize fluid accumulation)
- Intra-abdominal hypertension present
Adding Second-Line Vasopressors
When norepinephrine doses reach moderate levels, consider adding vasopressin rather than continuing to escalate 2:
- Add vasopressin 0.03 units/min when norepinephrine requirements are escalating
- This strategy may reduce catecholamine-related complications (arrhythmias, myocardial ischemia) 6, 9
- Alternatively, add epinephrine if additional agent needed 2
Administration Essentials
- Route: Central venous access preferred; use large vein with secure IV catheter 1
- Dilution: Must use dextrose-containing solutions (5% dextrose or dextrose-saline); saline alone causes potency loss 1
- Monitoring: Arterial line placement recommended for all patients requiring vasopressors 2
- Titration: Adjust continuously based on MAP response; avoid abrupt discontinuation 1
Key Pitfalls to Avoid
- Delaying norepinephrine in profound hypotension while pursuing fluid resuscitation alone—this prolongs hypotension and worsens outcomes
- Continuing to escalate norepinephrine beyond 0.5-1.0 mcg/kg/min without adding vasopressin or reassessing volume status
- Using saline-only dilutions, which cause oxidation and loss of drug potency 1
- Rigid adherence to MAP ≥65 mmHg in all patients—consider higher targets (up to 40 mmHg below baseline) in previously hypertensive patients 1